Latest News
Hamilton, Ontario, Canada and Boston, Massachusetts, USA. 10 January, 2022. Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced nomination of the first targeted alpha therapy […]
Hamilton, Canada and Boston, USA. 2 November 2021. Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, has announced the appointment of Christopher Leamon, Ph.D., as chief scientific […]